Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

NCT04040725 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawn per Bayer

Conditions

Bladder Cancer

Interventions

DRUG: Rogaratinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]